Administration of Interleukin 12 with pulse Interleukin 2 and the rapid and complete eradication of murine renal carcinoma

Journal of the National Cancer Institute

Volumn 88, Issue 1, 1996, Pages 38-43

  Wigginton, Jon M ^a   Komschlies, Kristin L ^b   Back, Timothy C ^b   Franco, José L ^a   Brunda, Michael J ^c   Wiltrout, Robert H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG ADMINISTRATION; KIDNEY; KIDNEY CARCINOMA; MOUSE; NEPHRECTOMY; NONHUMAN; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; INTERLEUKIN-12; INTERLEUKIN-2; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; PULSATILE FLOW; SURVIVAL ANALYSIS;

EID: 0030067276     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.1.38     Document Type: Article

References (38)

1. Brunda MJ. Interleukin-12. J Leukoc Biol 1994;55:280-8.
2. Chehimi J, Trinchieri G. Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J Clin Immunol 1994;14: 149-61.
3. Trinchieri G. Interleukin 12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-27.
4. Gately MK. Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors. Cancer Invest 1993;11:500-6.
5. Manetti R, Parronchi P, Gludizi MG, Piccinni MP, Maggi E, Trinchieri G, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993;177:1199-204.
6. Germann T, Gately MK, Schoenhaut DS, Lohoff M, Mattner F, Fischer S, et al. Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells. Eur J Immunol 1993;23:1826-30.
7. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993;177:1505-9.
8. Sypek JP, Chung CL, Major SE, Subramanyam JM, Goldman SJ, Sieburth DS, et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 1993;177:1797-802.
9. Clemons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994;38:460-4.
10. Gazzinelli RT, Giese NA, Morse HC. In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS). J Exp Med 1994;180:2199-208.
11. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A. Interleukin 12 is required for the T-lymphocyte independent induction of interferon-gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts [see comment citation in Medline]. Proc Natl Acad Sci U S A 1993;90:6115-9.
12. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994;153:1697-706.
13. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178:1223-30.
14. Brunda MJ, Luistro L, Hendrzak JA, Fouatoulakis M, Garotta G, Gately MK. The role of interferon-gamma in mediating the antitumor efficacy of interleukin 12. J Immunother 1995;17:71-7.
15. Maas RA, Dullens HF, Den Otter W. Interleukin-2 in cancer treatment: disappointing or (still) promising? A review. Cancer Immunol Immunother 1993;36:141-8.
16. Rubin JT. Interleukin-12: its biology and clinical application in patients with cancer. Cancer Invest 1993;11:460-72.
17. Smith KA. Lowest-dose interleukin-2 immunotherapy [see comment citation in Medline]. Blood 1993;81:1414-23.
18. Stahl M, Wilke HJ, Seeber S, Schmoll HJ. Cytokines and cytotoxic agents in renal cell carcinoma: a review. Semin Oncol 1992;19:70-9.
19. Bacon CM, McVicar DW, Ortaldo JR, Rees RC, O'Shea JJ, Johnson JA. Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. J Exp Med 1995;181:399-404.
20. Gately MK, Wilson DE, Wong HL. Synergy between recombinant interleukin 2 (rIL 2) and IL 2-depleted lymphokine-containing supernatants in faciliting allogeneic human cytolytic T lymphocyte responses in vitro. J Immunol 1986;136:1274-82.
21. Wong HL, Wilson DE, Jenson JC, Familletti PC, Stremlo DL, Gately MK. Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro. Cell Immunol 1988;111:39-54.
22. Stem AS, Podlaski FJ, Hulmes JD, Pan YC, Quinn PM, Wolitzky AG, et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci U S A 1990;87:6808-12.
23. Aste-Amezaga M, D'Andrea A, Kubin M, Trinchieri G. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell Immunol 1994;156:480-92.
24. + T lymphocytes. J Immunol 1993;151:2444-52.
25. Bertagnolli MM, Lin BY, Young D, Herrmann SH. IL-12 augments antigen-dependent proliferation of activated T lymphocytes. J Immunol 1992;149:3778-83.
26. + T lymphocytes, and NK cells. J Immunol 1992;149:3495-502.
27. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, Young HA, et al. Induction of interferon gamma production by natural killer stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 1991;173:869-79.
28. Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991;147:874-82.
29. Desai BB, Quinn PM, Wolitzky AG, Mongini PK, Chizzonite R, Gately MK. IL-12 receptor. II. Distribution and regulation of receptor expression. J Immunol 1992;148:3125-32.
30. Rossi AR, Pericle F, Rashleigh S, Janier J, Djeu JY. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 1994; 83:1323-8.
31. Huben RP, Connelly R, Goldrosen MH, Murphy GP, Pontes JE. Immunotherapy of a murine renal cancer. J Urol 1983;129:1075-8.
32. Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984;223:1412-5.
33. Wang A, Lu SD, Mark DF. Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues. Science 1984;224:1431-3.
34. Hornung RL, Back TC, Zaharko DS, Urba WJ, Longo DL, Wiltrout RH. Augmentation of natural killer activity, induction of IFN and development of tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.J Immunol 1988;141:3671-9.
35. Cui S, Reichner JS, Mateo RB, Albina JE. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Res 1994;54:2462-7.
36. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12 [see comment citation in Medline]. J Natl Cancer Inst 1995;87:581-6.
37. Franco JL, Ghosh P, Wiltrout RH, Carter CR, Zea AH, Momozaki N, et al. Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice. Cancer Res. In press.
38. Ghosh P, Sica A, Young HA, Ye J, Franco JL, Wiltrout RH, et al. Alterations in NF kappa B/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res 1994;54:2969-72.